[6-(Hydroxymethyl)thian-2-yl]methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 英文名称: [6-(Hydroxymethyl)thian-2-yl]methanol
• 化学式: C₇H₁₄O₂S
• mdl: MFCD08694096
• 分子量: 162.25
• InChiKey: VGVKVVZDXMDCAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  65.8
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Drugs for diabetes
  申请人：——

  公开号：US20040023890A1

  公开（公告）日：2004-02-05

  Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B) b0 —(C) c0 —NO 2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking group wherein the precursor must meet the tests described in the application, C is a a bivalent linking group as defined in the invention.

  用于治疗糖尿病的化合物或其盐，具有如下通用公式（I）：A-(B) b0 —(C) c0 —NO 2 其中A含有具有抗炎或镇痛活性的药物的自由基，B是一个双价连接基团，其中前体必须符合本申请中描述的测试，C是如发明中定义的双价连接基团。
• Pharmaceutical compounds
  申请人：Del Soldato Piero

  公开号：US20070197499A1

  公开（公告）日：2007-08-23

  Compounds or their salts of general formula (I): A-B—N(O) s wherein: s is an integer equal to 1 or 2; A=R-T 1 -, wherein R is the drug radical and T 1 =(CO) t or (X) t′ , wherein X═O, S, NR 1c , R 1c is H or a linear or branched alkyl or a free valence, t and t′ are integers and equal to zero or 1, with the proviso that t=1 when t′=0; t=0 when t′=1; B=-T B -X 2 —O—wherein T B =(CO) when t=0, T B =X when t′=0, X being as above defined; X 2 is equal to R 1B—X—R 2B radical wherein X is as above defined, R 1B and R 2B , equal to or different from each other, are linear or branched C 1 -C 6 alkylenes, or X 2 is a radical wherein two alkylene chains C 1 -C 4 are linked to nonadjacent positions of a central ring having 4 or 6 atoms, said ring being an unsaturated cycloaliphatic ring, or a saturated or aromatic heterocylic ring, containing one or two heteroatoms, equal or different, selected from O, S, N; wherein the unsaturated cycloaliphatic ring does not have aromatic character according to Huckel's rule.

  通式(I)的化合物或其盐：A-B-N（O）s其中：s是等于1或2的整数；A = R-T1-，其中R为药物基团，T1 =（CO）或（X）t'，其中X = O，S，NR1c，R1c是H或线性或支链烷基或自由价，t和t'是整数，等于零或1，但前提是当t' = 0时，t = 1；当t' = 1时，t = 0；B = -TB-X2-O-，其中TB =（CO）当t = 0时，TB = X当t' = 0时，X如上定义；X2等于R1B-X-R2B基团，其中X如上定义，R1B和R2B相等或不同，是线性或支链C1-C6烷基，或X2是基团，其中两个C1-C4烷基链连接到具有4或6个原子的中心环的非相邻位置，该环是不饱和的环状脂肪族环，或饱和的或芳香的杂环，包含一个或两个异原子，相同或不同，从O，S，N中选择；其中不饱和的环状脂肪族环不具有根据Huckel法则的芳香性质。
• Pharmaceutical Compounds
  申请人：SOLDATO Piero Del

  公开号：US20090170941A1

  公开（公告）日：2009-07-02

  Compounds or their salts of general formula (I): A-B—N(O) s wherein: s is an integer equal to 1 or 2; A=R-T 1 -, wherein R is the drug radical and T 1 =(CO) t or (X) t′ , wherein X=O, S, NR 1c , R 1c is H or a linear or branched alkyl or a free valence, t and t′ are integers and equal to zero or 1, with the proviso that t=1 when t′=0; t=0 when t′=1; B=-T B -X 2 —O— wherein T B =(CO) when t=0, T B =X when t′=0, X being as above defined; X 2 is equal to R 1B —X—R 2B radical wherein X is as above defined, R 1B and R 2B , equal to or different from each other, are linear or branched C 1 -C 6 alkylenes, or X 2 is a radical wherein two alkylene chains C 1 -C 4 are linked to nonadjacent positions of a central ring having 4 or 6 atoms, said ring being an unsaturated cycloaliphatic ring, or a saturated or aromatic heterocylic ring, containing one or two heteroatoms, equal or different, selected from O, S, N; wherein the unsaturated cycloaliphatic ring does not have aromatic character according to Huckel's rule.

  通式（I）的化合物或其盐：A-B-N（O）s，其中：s是等于1或2的整数；A=R-T1-，其中R是药物基团，T1=（CO）或（X）t′，其中X=O、S、NR1c、R1cis H或线性或支链烷基或自由价，t和t′是整数且等于零或1，但是当t′=0时，t=1；当t′=1时，t=0；B=-TB-X2-O-，其中TB=（CO）当t=0时，TB=X当t′=0时，X如上定义；X2等于R1B-X-R2Bradical，其中X如上定义，R1B和R2B，相等或不同于彼此，是线性或支链C1-C6烷基，或X2是一个基团，其中两个C1-C4烷基链连接到一个中心环的非相邻位置，该环具有4或6个原子，该环是一个不饱和的环状脂肪环，或者是一个含有一个或两个异原子的饱和或芳香族杂环，相同或不同，所选异原子为O、S、N；其中，不饱和的环状脂肪环不具有根据Huckel规则的芳香性。
• Nitric esters derivatives of ferulic acid and sulindac with pharmaceutical activity
  申请人：Nicox S.A

  公开号：EP1593664A1

  公开（公告）日：2005-11-09

  Compounds or their salts of general formula (I): A-B-N(O)2 wherein: A is a drug radical selected from ferulic acid and sulindac; B= -O-R1B-X-R2B-O- wherein R1B and R2B, equal to or different from each other, are linear or branched C1-C6 alkylenes, and X = a free valence or O, S, NR1C, R1C is H or a linear or branched alkyl, having from 1 to 6 carbon atoms.

  通式(I)的化合物或其盐类：A-B-N(O)2 其中： A 是选自阿魏酸和舒林酸的药物自由基； B= -O-R1B-X-R2B-O- 其中 R1B 和 R2B，彼此相同或不同，是线性或支链 C1-C6 烷基，以及 X = 自由价或 O、S、NR1C，R1C 是 H 或具有 1 至 6 个碳原子的直链或支链烷基。
• Modifiable polyunsaturated polymers and processes for their preparation
  申请人：Parthiban Anbanandam

  公开号：US20060189774A1

  公开（公告）日：2006-08-24

  The present invention relates to modifiable linear polyunsaturated polymers and processes for preparing the same comprising reacting solely at least one bifunctional nucleophilic compound with at least one α-functional unsaturated monomer. The at least one bifunctional nucleophilic compound of the invention comprises two nucleophiles independently selected from the group consisting of C, N, O, S and Se. The at least one α-functional unsaturated monomer of the invention comprises two leaving groups L 1 and L 2 , wherein at least one of the leaving groups L 1 and L 2 of the at least one α-functional unsaturated monomer is part of the nonaromatic unsaturated structure C═C—C α -L. The double bond of said α-functional unsaturated monomer is maintained in the polyunsaturated polymer.

  本发明涉及可改性线性多不饱和聚合物以及制备该聚合物的工艺，包括仅使至少一种双官能团亲核化合物与至少一种α官能团不饱和单体反应。本发明的至少一种双官能团亲核化合物包括两个独立选自 C、N、O、S 和 Se 组的亲核物。本发明的至少一种 α-官能团不饱和单体包括两个离去基团 L 1 和 L 2 其中至少一个离去基团 L 1 和 L 2 的至少一个离去基团 L 1 和 L 2 是非芳香族不饱和结构 C═C-C α -L.所述 α-官能团不饱和单体的双键保留在多不饱和聚合物中。